• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Changes in the uptake of screening for prostate cancer with prostate-specific antigen in Ontario between 2003 to 2012.2003年至2012年间安大略省前列腺特异性抗原前列腺癌筛查的接受情况变化。
Can Oncol Nurs J. 2020 Apr 1;30(2):125-132. doi: 10.5737/23688076302125132. eCollection 2020 Spring.
2
Prostate-specific antigen utilization in Ontario: extent of testing in patients with and without cancer.安大略省前列腺特异性抗原的应用:癌症患者与非癌症患者的检测范围
Clin Biochem. 1998 Aug;31(6):501-11. doi: 10.1016/s0009-9120(98)00052-6.
3
Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.基于前列腺特异性抗原(PSA)的前列腺癌人群筛查:一项经济学分析。
Ont Health Technol Assess Ser. 2015 May 1;15(11):1-37. eCollection 2015.
4
Prostate-specific antigen (PSA) screening rates and factors associated with screening in Eastern Canadian men: Findings from cross-sectional survey data.加拿大东部男性的前列腺特异性抗原(PSA)筛查率及与筛查相关的因素:横断面调查数据的研究结果
Can Urol Assoc J. 2020 Jul;14(7):E319-E327. doi: 10.5489/cuaj.6072.
5
Factors Related to Prostate-Specific Antigen-Based Prostate Cancer Screening in Primary Care: Retrospective Cohort Study of 120,587 French Men Over the Age of 50 Years.基层医疗中基于前列腺特异性抗原的前列腺癌筛查相关因素:对120587名50岁以上法国男性的回顾性队列研究。
JMIR Public Health Surveill. 2018 Oct 23;4(4):e10352. doi: 10.2196/10352.
6
Associations of Prostate-Specific Antigen (PSA) Testing in the US Population: Results from a National Cross-Sectional Survey.美国人群中前列腺特异性抗原(PSA)检测的相关性:一项全国性横断面调查的结果。
J Community Health. 2021 Apr;46(2):389-398. doi: 10.1007/s10900-020-00923-8. Epub 2020 Oct 16.
7
Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer.安大略省的前列腺特异性抗原检测:对未确诊前列腺癌患者进行检测的原因
CMAJ. 1999 Jan 12;160(1):70-5.
8
Ever and Annual Use of Prostate Cancer Screening in African American Men.非裔美国男性前列腺癌筛查的长期及年度使用情况。
Am J Mens Health. 2017 Jan;11(1):99-107. doi: 10.1177/1557988315596225. Epub 2016 Jul 8.
9
Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.机会性检测与有组织的前列腺特异性抗原筛查:哥德堡随机人群前列腺癌筛查试验 18 年后的结果。
Eur Urol. 2015 Sep;68(3):354-60. doi: 10.1016/j.eururo.2014.12.006. Epub 2014 Dec 31.
10
Opportunistic prostate cancer screening: A population-based analysis.机会性前列腺癌筛查:基于人群的分析。
Urol Oncol. 2020 May;38(5):393-400. doi: 10.1016/j.urolonc.2019.12.009. Epub 2020 Jan 14.

本文引用的文献

1
Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates.近期全球前列腺癌发病率和死亡率模式。
Eur Urol. 2020 Jan;77(1):38-52. doi: 10.1016/j.eururo.2019.08.005. Epub 2019 Sep 5.
2
Screening for prostate cancer: History, evidence, controversies and future perspectives toward individualized screening.前列腺癌筛查:历史、证据、争议以及个体化筛查的未来展望。
Int J Urol. 2019 Oct;26(10):956-970. doi: 10.1111/iju.14039. Epub 2019 Jun 10.
3
Recent trends in prostate cancer in Canada.加拿大前列腺癌的最新趋势。
Health Rep. 2019 Apr 17;30(4):12-17. doi: 10.25318/82-003-x201900400002-eng.
4
Prostate cancer screening: where are we now?前列腺癌筛查:我们目前处于什么阶段?
BJU Int. 2019 Jun;123(6):916-917. doi: 10.1111/bju.14692. Epub 2019 Feb 19.
5
What Is the Effectiveness of Patient Decision Aids for Cancer-Related Decisions? A Systematic Review Subanalysis.患者决策辅助工具对癌症相关决策的有效性如何?一项系统评价子分析。
JCO Clin Cancer Inform. 2018 Dec;2:1-13. doi: 10.1200/CCI.17.00148.
6
Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.基于前列腺特异性抗原的前列腺癌筛查:美国预防服务工作组的证据报告和系统评价。
JAMA. 2018 May 8;319(18):1914-1931. doi: 10.1001/jama.2018.3712.
7
Implications of false-positive results for future cancer screenings.假阳性结果对未来癌症筛查的影响。
Cancer. 2018 Jun 1;124(11):2390-2398. doi: 10.1002/cncr.31271. Epub 2018 Apr 23.
8
Can active surveillance really reduce the harms of overdiagnosing prostate cancer? A reflection of real life clinical practice in the PRIAS study.主动监测真的能减少前列腺癌过度诊断的危害吗?PRIAS研究对现实生活临床实践的思考。
Transl Androl Urol. 2018 Feb;7(1):98-105. doi: 10.21037/tau.2017.12.28.
9
Men's perspectives of prostate cancer screening: A systematic review of qualitative studies.男性对前列腺癌筛查的看法:定性研究的系统评价
PLoS One. 2017 Nov 28;12(11):e0188258. doi: 10.1371/journal.pone.0188258. eCollection 2017.
10
Can you un-ring the bell? A qualitative study of how affect influences cancer screening decisions.能否覆水难收?影响癌症筛查决策的情感因素定性研究。
BMC Cancer. 2017 Sep 13;17(1):647. doi: 10.1186/s12885-017-3596-7.

2003年至2012年间安大略省前列腺特异性抗原前列腺癌筛查的接受情况变化。

Changes in the uptake of screening for prostate cancer with prostate-specific antigen in Ontario between 2003 to 2012.

作者信息

Watson Louis

机构信息

email:

出版信息

Can Oncol Nurs J. 2020 Apr 1;30(2):125-132. doi: 10.5737/23688076302125132. eCollection 2020 Spring.

DOI:10.5737/23688076302125132
PMID:33118992
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7586704/
Abstract

OBJECTIVES

This study investigates change in prostate-specific antigen (PSA) screening uptake in Ontario among men 35 years of age and older, between 2003 and 2012. We identify factors related to PSA testing, and examine the degree to which age guidelines for PSA testing are being followed or if PSA screening is opportunistic in nature. The relationship of income, education and having a regular physician and an estimation of PSA testing prevalence in 2012 is also studied.

METHODS

Data from the Canadian Community Health Survey (CCHS) were used to estimate the proportion of men who had a PSA test in 2003 and then compared to a similar estimate (in similar population) in 2012. We also examined associations with PSA uptake to socio-demographic factors. Contingency table analyses were performed to characterize the changes; logistic regression was also used to evaluate the differences, while taking into account the possible confounding role of other factors.

RESULTS

We found among men aged 35-49 years and 75+, there was an increase in PSA utilization between 2003 and 2012. In 2003, 18% of men 35-49 years, and 74% of men aged 75+ reported ever having a PSA test. These figures increased to 20% of men aged 35-49 years, and 84% of men aged 75+ years in 2012. Logistic regression showed that a man in the 70-74 age category in 2012 had the highest likelihood of having had a PSA test compared to men in the age range of 35-49 years (odds ratio (OR)=25.9; confidence interval (CI)= 19.9-33.8).

CONCLUSION

In Ontario, PSA testing is seemingly opportunistic in nature and occurring in groups not recommended for testing by the Ontario guidelines. There is a marked increase in PSA utilization in age ranges outside of the current Ontario PSA testing guidelines (35-49 and 75+). It would appear that most PSA testing in Ontario is opportunistic and adherence to age guidelines is limited.

摘要

目的

本研究调查了2003年至2012年间安大略省35岁及以上男性前列腺特异性抗原(PSA)筛查的接受情况变化。我们确定与PSA检测相关的因素,并检查遵循PSA检测年龄指南的程度,或者PSA筛查是否本质上是机会性的。还研究了收入、教育程度、是否有固定医生与2012年PSA检测患病率估计之间的关系。

方法

使用加拿大社区健康调查(CCHS)的数据来估计2003年进行PSA检测的男性比例,然后与2012年(类似人群中)的类似估计进行比较。我们还研究了PSA接受情况与社会人口因素之间的关联。进行列联表分析以描述变化情况;在考虑其他因素可能的混杂作用时,还使用逻辑回归来评估差异。

结果

我们发现,在35 - 49岁和75岁以上的男性中,2003年至2012年间PSA检测的使用率有所增加。2003年,35 - 49岁男性中有18%,75岁以上男性中有74%报告曾进行过PSA检测。2012年,这些数字分别增至35 - 49岁男性中的20%和75岁以上男性中的84%。逻辑回归显示,与35 - 49岁年龄组的男性相比,2012年70 - 74岁年龄组的男性进行PSA检测的可能性最高(优势比(OR)=25.9;置信区间(CI)=19.9 - 33.8)。

结论

在安大略省,PSA检测似乎本质上是机会性的,并且在安大略省指南不建议检测的人群中进行。在当前安大略省PSA检测指南范围之外的年龄组(35 - 49岁和75岁以上),PSA检测的使用率有显著增加。看来安大略省的大多数PSA检测是机会性的,对年龄指南的遵循有限。